|
|
|
| home > news |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
|
|
Terebellum, Ireland and UK-based Life Sciences Solutions Provider, Announces Appointments Following Expansion into New Markets
More>> |
|
|
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
Cellaca® PLX Image Cytometer redefines workflows, addresses multiple Critical Quality Attributes
September 26, 2022, WALTHAM, Mass.: PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. More>> |
|
|
Novartis Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya® (fingolimod) Dosing Regimen Patent
Basel, 21 September, 2022 — Today, Novartis announced that the U.S.
Court of Appeals for the Federal Circuit (CAFC) has denied its petition
to rehear the negative decision regarding the validity of US Patent No.
9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans
to file a petition seeking further review of the CAFC’s decision with
the US Supreme Court. More>> |
|
|
Quinten Health Closes its Financing Round to Advance Disease Modelling Platforms and Virtual Twins in Real-World
Paris, September 21st, 2022 – Life Science Newswire – QUINTEN
HEALTH, a pioneer in real-world data science, Artificial Intelligence
(AI) and Machine Learning (ML) for precision care, today announces that
it has closed its financing round to advance disease modeling platforms
and virtual twins in real-world, as part of the Quinten Group's €14
million growth equity investment from TECHLIFE CAPITAL and MACSF,
essentially dedicated to the healthcare activities of the Quinten group. More>> |
|
|
LifeArc Joins Forces with Cystic Fibrosis Trust and Medicines Discovery Catapult to Strengthen Antimicrobial Discovery Efforts
Pivotal partnership seeks to transform Cystic Fibrosis research
LifeArc, a national medical research charity, is joining the Cystic
Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate in a strategic
partnership alongside Cystic Fibrosis Trust and Medicines Discovery
Catapult (MDC). More>> |
|
|
Paradigm Clinical Research Names Industry Veteran Kurt Mussina as CEO as Expansion Plans Are Set in Motion
More>> |
|
|
ACG appoints Shankar Gupta as Chief Sales Officer
Industry authority to re-join business in a newly created role
ACG, the world’s largest integrated pharmaceutical and nutraceutical manufacturing solutions provider, is delighted to announce that Shankar Gupta will be re-joining the business in the newly created role of chief sales officer.
More>> |
|
|
+91 022 7186 2362 / +91 022 7186 2363
|
|
www.acg-world.com/
|
|
D Bhabrekar Nagar Road Mumbai, Maharashtra 400067, IN
|
| |
|
FlyPharma Conference Europe 2022 Shares the Latest Supply Chain Challenges and Advice for Better Industry Collaboration
On 20-21 September 2022, the FlyPharma Conference Europe made a
welcome return as a live, in-person event. The conference was warmly
received by its delegates and declared a resounding success, with some
familiar faces from previous events and many new ones in attendance
across the two days. More>> |
|
|
Elligo’s Rebecca Kush, Ph.D., Elected Chair of Vulcan Advisory Council: Connecting Clinical Research and Healthcare
More>> |
|
|
WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research
More>> |
|
|
|
 |
|
|
 |
News and Press Releases |
 |
FUJIFILM Irvine Scientific Acquires Exclusive License for Artificial Intelligence for IVF
SANTA ANA, Calif., June 22, 2022: FUJIFILM Irvine Scientific,
Inc., a world leader in the innovation, development, and manufacture of
cell culture media and assisted reproductive technologies (ART), today
announced it has exclusively licensed the intellectual property relating
to artificial intelligence (AI) for image-based evaluation of human
embryos to improve in-vitro fertilization (IVF) success rates. The
technology was developed and patented jointly by investigators from
Brigham and Women’s Hospital and Massachusetts General Hospital with
expertise in artificial intelligence, biomedical engineering and IVF.
Terms of the deal were not disclosed.
More info >> |
|
 |
White Papers |
 |
|
The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation
BioPharmaSpec
1. Introduction
As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >> |
|
|
